Investment Research Analysts’ Latest Ratings Updates for Novartis AG (NVS)

Investment Research Analysts’ Latest Ratings Updates for Novartis AG (NVS)

Several brokerages have updated their recommendations and price targets on shares of Novartis AG (NYSE: NVS) in the last few weeks:

Shares of Novartis AG (NYSE:NVS) traded down 0.36% during mid-day trading on Tuesday, reaching $74.83. 1,934,093 shares of the company traded hands. The company has a market capitalization of $177.65 billion, a P/E ratio of 26.73 and a beta of 0.73. The stock’s 50-day moving average is $75.57 and its 200-day moving average is $74.18. Novartis AG has a 52 week low of $66.93 and a 52 week high of $83.58.

Novartis AG (NYSE:NVS) last announced its earnings results on Wednesday, January 25th. The company reported $1.12 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.12. The company earned $12.32 billion during the quarter, compared to analysts’ expectations of $12.44 billion. Novartis AG had a net margin of 13.80% and a return on equity of 15.37%. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.14 earnings per share. On average, equities analysts predict that Novartis AG will post $4.70 EPS for the current fiscal year.

The firm also recently announced an annual dividend, which was paid on Friday, March 3rd. Shareholders of record on Friday, March 3rd were given a dividend of $2.327 per share. The ex-dividend date of this dividend was Wednesday, March 1st. Novartis AG’s payout ratio is currently 82.14%.

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Related posts

Leave a Comment